Internal Medicine, Clinical Cardiatric Electrophysiology · Mesa, AZ
NPI
1366491441
Since 2006
Specialty
Internal Medicine, Clinical Cardiatric Electrophysiology
Code 207RC0001X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
6750 E Baywood Ave, 301
Mesa, AZ, 85206
Phone (480) 835-6100
Groups this clinician bills Medicare through
Medicare paid, 2024
$837K
12,997 services
Medicare patients, 2024
1,950
Average age 77
Drug cost, 2024
$2.4M
10,026 prescriptions
Company payments, 2025
$2,608
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kai-Chun Sung was code 93296 (external electrocardiographic monitoring), 2,075 times for 718 patients. In total Kai-Chun Sung billed 12,997 services in 95 codes, and Medicare paid $837K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-03-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93296 External Electrocardiographic Monitoring | Office | 2,075 | 718 | $16.07 | $33K |
| 99214 Office E&M - Established | Office | 1,736 | 1,102 | $89.36 | $155K |
| 93000 Electrocardiogram | Office | 1,486 | 1,093 | $10.34 | $15K |
| 93294 External Electrocardiographic Monitoring | Office | 1,428 | 492 | $22.18 | $32K |
| 93298 External Electrocardiographic Monitoring | Office | 739 | 101 | $73.06 | $54K |
| 93295 External Electrocardiographic Monitoring | Office | 653 | 228 | $27.56 | $18K |
| 93280 External Electrocardiographic Monitoring | Office | 548 | 405 | $58.89 | $32K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 520 | 130 | $5.41 | $2,815 |
| 93793 Care Management/Coordination | Office | 430 | 64 | $7.85 | $3,377 |
| 93306 Echocardiography (TTE/TEE) | Office | 383 | 363 | $132.79 | $51K |
| 85610 Clinical Chemistry | Office | 342 | 59 | $4.20 | $1,436 |
| 93015 Electrocardiogram | Office | 201 | 201 | $48.55 | $9,758 |
| A9500 Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 172 | 86 | $23.89 | $4,108 |
| 93284 External Electrocardiographic Monitoring | Office | 170 | 110 | $79.15 | $13K |
| 93283 External Electrocardiographic Monitoring | Office | 166 | 110 | $72.72 | $12K |
By year: 2022 $898K for 14,187 services; 2023 $832K for 13,124 services; 2024 $837K for 12,997 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 342 | 59 | $4.20 | $1,436 |
Medicare prescription drug claims, 2024
In 2024, the drug Kai-Chun Sung prescribed most often to Medicare patients was Eliquis (Apixaban), with 847 prescriptions and refills. In total Kai-Chun Sung wrote 10,026 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 847 | 1,999 | 258 | $1.1M |
| Metoprolol Tartrate Generic | 608 | 1,679 | 194 | $4,226 |
| Carvedilol Generic | 608 | 1,719 | 197 | $6,135 |
| Metoprolol Succinate Generic | 597 | 1,546 | 264 | $8,027 |
| Losartan Potassium Generic | 579 | 1,584 | 180 | $5,796 |
| Sotalol Sotalol Hcl | 502 | 1,461 | 174 | $14K |
| Lisinopril Generic | 422 | 1,223 | 150 | $3,044 |
| Atorvastatin Calcium Generic | 405 | 1,206 | 126 | $4,046 |
| Rosuvastatin Calcium Generic | 335 | 948 | 119 | $4,158 |
| Furosemide Generic | 327 | 885 | 121 | $2,051 |
| Entresto Sacubitril/Valsartan | 327 | 738 | 94 | $480K |
| Flecainide Acetate Generic | 314 | 789 | 99 | $15K |
| Spironolactone Generic | 272 | 771 | 100 | $2,196 |
| Amlodipine Besylate Generic | 266 | 761 | 95 | $1,887 |
| Amiodarone Hcl Generic | 200 | 538 | 95 | $6,688 |
Brand drugs: 1,817 claims; generic drugs: 8,209 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kai-Chun Sung $2,608 ($2,608 in general payments such as food, travel and fees) from 7 companies. The largest payer was Abbott Laboratories with $2,219.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.